|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
CO-ADMINISTRATION CAN LEAD TO HIGH SERUM CONCENTRATION OF ACETAZOLAMIDE DUE TO COMPITITION AT RENAL TUBULES FOR SECRETION AND TOXICITY LEADING TO ANOREXIA,TACHYCARDIA,LETHARGYNESS,COMA & DEATH
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
G.I. SIDE EFFECTS & RENAL SIDE EFFECTS ARE INCREASED WITH CONCURRENT ADMINISTRATION OF NSAIDS
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
GUAR GUM WHEN COMCOMITANTLY ADMINISTERED WITH OTHER DRUGS, MAY RETARD THEIR ABSORPTION
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS INHIBIT SPREADING ACTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
MAY HAVE ADDITIVE EFFECT ON THE NEPHROTOXICITY OF ASPIRIN
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
ANTACIDS MAY INCREASE ITS EXCRETION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|